Forgot Password?
Return to Course Listing

CME: Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

Activity Description / Statement of Need:

In this online CME self-learning program:

Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.The disease may arise from any of a number of genetic mutations of the complement system or the presence of anti-complement factor H. While it is estimated to occur at an equally commonly between males and females, the disease is rare with an estimated incidence of about 2 people per million in the U.S. and seven per million in Europe.

Target Audience:

The following healthcare professionals: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.


This activity is supported by an educational grant from Alexion

This activity is free of charge


Release Date: July 10, 2019 -- Expiration Date: July 10, 2021

Faculty: Ramy Hanna, MD

Agenda

Introduction

Epidemiology

  • Current statistics
  • Risk and causes

Pathophysiology and diagnosis, future complications [Learning objectives #1 and #2]

  • Clinical features 
    • Microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury, abdominal pain, fatigue, nausea/vomiting 
  • Diagnostic methods 
    • Clinical presentation, screening for mutations and antibodies to complement proteins, screening for Shiga toxin-producing E. coli 

Treatment [Learning objectives #3 and #4]

  • Present therapy 
    • Eculizumab
    • Plasma exchange or infusion
    • Renal or combination renal-hepatic transplantation
  • Supportive care
  • Investigational therapies 
    • Ravulizumab
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
  • Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
  • Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
  • Design an evidence-based treatment plan for a patient with aHUS

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation: ScientiaCME designates this educational activity for a maximum of  1.00 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PhysiciansFor maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.00 hours (0.10 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-19-021-H01-P.  ACPE Accreditation effective 7/14/19 and expires 7/14/21. This is a Knowledge (K)-type activity.

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Ramy Hanna, MD, Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA, is a consultant for Alexion pharmaceuticals.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Alexion

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

Hemophilia A: Therapeutic Updates, Emerging Therapies, and Barriers to Care

Hemophilia B: Therapeutic Updates, Emerging Therapies, and Barriers to Care